Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

The following is a summary of "Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

These findings align with the proposed mechanism of action for the therapy that involves targeting malignant cells ... first-line HCC patients.” Hepatocellular carcinoma is a rapidly progressing ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Hepatocellular carcinoma (HCC) represents a significant ... (APHE), present a diagnostic challenge and a significant risk of ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given ...

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to ...